Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Th
Post# of 124
(Total Views: 168)
Posted On: 02/21/2024 4:36:16 PM
Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs
- Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets
- The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage
- The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies
Sigyn Therapeutics (OTCQB: SIGYD, SIGY), a development-stage medical technology company creates therapeutic candidates with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in global health, and 2) their successful clinical advancement would provide a potential competitive advantage within an established therapeutic industry segment.
The company’s therapeutic candidates include:
- Sigyn Therapy(TM) – to treat pathogen-associated conditions that are not addressed with FDA-approved drugs
- ImmunePrep(TM) – a platform to enhance the performance of therapeutic antibodies to treat cancer
- ChemoPrep(TM) – to improve the delivery of cancer chemotherapies
- ChemoPure(TM) – to reduce the post-treatment toxicity of chemotherapy
Sigyn Therapy(TM) is a novel blood purification technology being advanced to treat pathogen-associated inflammatory disorders. To date, in vitro studies have demonstrated the ability of Sigyn Therapy(TM) to reduce the circulating prevalence of twelve different pathogen and inflammatory disease targets from human blood plasma. Based on these outcomes, candidate treatment indications include community-acquired pneumonia, endotoxemia, drug resistant viral and bacterial infections, and sepsis, the leading cause of hospital deaths in the United States. First-in-human feasibility studies of Sigyn Therapy(TM) plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population.
ImmunePrep(TM) is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for nine of the top 15 best-selling cancer treatment drugs. ChemoPrep(TM) is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPure(TM) extracts off-target chemotherapy from the bloodstream to reduce patient toxicity.
Sigyn Therapeutics CEO, James A. Joyce, on the inspiration for ChemoPrep and ChemoPure stated, “They were designed to improve cancer patient outcomes and improve quality of life based on the unfortunate reality that a vast majority of chemotherapy is not delivered to intended tumor cell targets and off-target chemotherapy remaining in the bloodstream is more likely to contribute to patient toxicity versus therapeutic benefit.”
For more information, visit the company’s website at www.SigynTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets
- The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage
- The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies
Sigyn Therapeutics (OTCQB: SIGYD, SIGY), a development-stage medical technology company creates therapeutic candidates with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in global health, and 2) their successful clinical advancement would provide a potential competitive advantage within an established therapeutic industry segment.
The company’s therapeutic candidates include:
- Sigyn Therapy(TM) – to treat pathogen-associated conditions that are not addressed with FDA-approved drugs
- ImmunePrep(TM) – a platform to enhance the performance of therapeutic antibodies to treat cancer
- ChemoPrep(TM) – to improve the delivery of cancer chemotherapies
- ChemoPure(TM) – to reduce the post-treatment toxicity of chemotherapy
Sigyn Therapy(TM) is a novel blood purification technology being advanced to treat pathogen-associated inflammatory disorders. To date, in vitro studies have demonstrated the ability of Sigyn Therapy(TM) to reduce the circulating prevalence of twelve different pathogen and inflammatory disease targets from human blood plasma. Based on these outcomes, candidate treatment indications include community-acquired pneumonia, endotoxemia, drug resistant viral and bacterial infections, and sepsis, the leading cause of hospital deaths in the United States. First-in-human feasibility studies of Sigyn Therapy(TM) plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population.
ImmunePrep(TM) is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for nine of the top 15 best-selling cancer treatment drugs. ChemoPrep(TM) is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPure(TM) extracts off-target chemotherapy from the bloodstream to reduce patient toxicity.
Sigyn Therapeutics CEO, James A. Joyce, on the inspiration for ChemoPrep and ChemoPure stated, “They were designed to improve cancer patient outcomes and improve quality of life based on the unfortunate reality that a vast majority of chemotherapy is not delivered to intended tumor cell targets and off-target chemotherapy remaining in the bloodstream is more likely to contribute to patient toxicity versus therapeutic benefit.”
For more information, visit the company’s website at www.SigynTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)